PhaseRx reported financial results for the second quarter and six months ended June 30, 2017. For the quarter, net loss was $3.5 million, or $0.30 per share, compared to a net loss of $11.1 million, or $1.84 per share, for the quarter ended June 30, 2016. Loss from operations was $3.32 million compared to $9.811 million a year ago. For the six months, the company reported net loss of $7.7 million, or $0.66 per share, compared to a net loss of $13.32 million, or $4.05 per share, for the quarter ended June 30, 2016. Loss from operations was $7.24 million compared to $11.924 million a year ago.